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Survival for patients diagnosed with mantle cell lymphoma (MCL) has
improved drastically in recent years. However, patients carrying mutations
in tumour protein p53 (TP53) do not benefit from modern chemotherapy-
based treatments and have poor prognosis. Thus, there is a clinical need to
identify missense mutations through routine analysis to enable patient
stratification. Sequencing is not widely implemented in clinical practice for
MCL, and immunohistochemistry (IHC) is a feasible alternative to identify
high-risk patients. The aim of the present study was to investigate the accu-
racy of p53 as a tool to identify patients with TP53 missense mutations
and the prognostic impact of overexpression and mutations in a Swedish
population-based cohort. In total, 317 cases were investigated using IHC
and 255 cases were sequenced, enabling analysis of p53 and TP53 status
among 137 cases divided over the two-cohort investigated. The accuracy of
predicting missense mutations from protein expression was 82%, with sen-
sitivity at 82% and specificity at 100% in paired samples. We further show
the impact of p53 expression and TP53 mutations on survival (hazard ratio
of 31 in univariate analysis for both), and the association to risk factors,
such as high MCL International Prognostic Index, blastoid morphology
and proliferation, in a population-based setting.
Keywords: immunohistochemistry, p53, TP53, mantle cell lymphoma, digi-
tal pathology, targeted sequencing.
Mantle cell lymphoma (MCL) is a rare and aggressive mature
B-cell lymphoma with a historically median overall survival
(OS) of 3–5 years.1 Sub-groups of young and fit patients
have benefitted from modern treatment such as the Nordic
MCL2/3 protocol, which includes cytarabine, rituximab and
consolidation with high-dose therapy and autologous stem-
cell transplantation, and can achieve longer survival times.2
In contrast, high-risk patients identified by the MCL Inter-
national Prognostic Index (MIPI), blastoid morphology or
tumour protein p53 (TP53) mutational status still have a
short survival. Patients with MCL with TP53 mutated cells
have a median OS of 18 compared to 127 years in patients
with TP53 wild-type (WT) MCL tumours.3 Patients with
mutated TP53 tumours also have a shorter progression-free
survival and higher incidence of relapse, with hazard ratios
(HRs) of 68 and 69, respectively, in a multivariate analysis
including MIPI and blastoid morphology.3 Further, multiple
studies have reported higher frequency of TP53 mutations in
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groups of patients with blastoid morphology and highly pro-
liferative tumours.4–7 Mutations are also more frequent
among relapsed (22%) compared to diagnostic (10%)
patients, as shown in the PHILEMON clinical trial (Clini-
calTrials.gov Identifier: NCT02460276).8 This was also rein-
forced by the AIM clinical trial (ClinicalTrials.gov Identifier:
NCT02471391), where half of the patients had TP53 aberra-
tions.9
It is known that deletions of TP53 in MCL are less signifi-
cant than mutations (HR 14 vs. 62, respectively),3 and they
lose significance in multivariate analysis, emphasising the rel-
evance of combining TP53 mutations with MIPI for risk
stratification, rather than deletions.10
Despite association to other high-risk characteristics, TP53
mutated MCLs cannot be identified based on morphology or
proliferation,8 supporting that assessment of TP53 status
needs to be used for improved risk stratification. Targeted
sequencing is not available in most clinics and alternative
methods are warranted. It is known that missense mutations
may lead to accumulation of the protein in the cell,11,12
which can be identified through routine immunohistochem-
istry (IHC).13 Currently, p53 expression is being widely
accepted as a marker for TP53 missense mutation in other
malignancies.14–16
Information on TP53 status may guide treatment selec-
tion, as chemotherapy-free treatment, which is independent
on functional DNA repair pathways, could provide an alter-
native for patients with TP53 mutated malignancies. This
was supported by a study where relapsed MCL patients trea-
ted with ibrutinib, lenalidomide and rituximab, responded
equally to the treatment independent of their TP53 muta-
tional status.8
In the present study, we aimed to investigate the accu-
racy of p53 as a tool to identify patients with TP53 mis-
sense mutations and investigate the prognostic impact of
overexpression and mutations in a Swedish population-
based cohort of patients. We show that p53 identifies MCL
tumours with TP53 missense mutations with high accuracy,
and that sub-clones of p53-positive tumour cells can be
identified when whole tissue sections are used. We further
report on the prognostic impact of both TP53 mutations
and p53 overexpression, emphasising the importance in
identifying these high-risk patients. We propose that risk
stratification using routine IHC staining of p53 should be
used to stratify patients with MCL to alternative treatment
options.
Patients and methods
Patient characteristics, IHC protocols and quantification
In the present study, material from diagnostic MCL patients,
part of the population-based cohorts BLISS (Biobank of
Lymphomas in Southern Sweden) and F1 (Finnish MCL
patients) and the Nordic MCL2 and MCL3 (N-MCL2/3)
clinical trials,17,18 were used (Fig 1 and Data S1; Patient
characteristics).
Tissue microarrays (TMAs) were constructed as previously
described.19 Briefly, representative 1-mm tumour areas were
transferred to a recipient block using an automated device
(ATA-27; Beecher Instruments, Sun Prairie, WI, USA). The
Benchmark Ultra Ventana platform (Roche, Basel, Switzer-
land) was used to stain TMAs with anti-p53, anti-cyclin D1,
anti-SRY-box transcription factor (SOX11) and anti-Ki-67
(Table SI). Scanning (940) was performed using a NanoZoo-
mer 60 (Hamamatsu Photonics, Hamamatsu, Shizuoka,
Japan).
Two methods were used to quantify p53 expression:
manual scoring based on routine clinical pathology proce-
dures and digital software HALO (Indica Labs, Albu-
querque, NM, USA). Manual pathology review was
performed by a trained pathologist and staining was con-
sidered when nuclei were dark brown, as this has been
shown to correlate to the presence of mutations.20 Faint
staining was not considered. Cores with >30% positive
nuclei were classified as p53-overexpression cases and the
others as low p53-expressing cores. The cut-off was selected
based on clinical routine at Lund University Hospital, and
consistent with previous publications from the Nordic lym-
phoma group.10
For digital pathology scoring, the Cytonuclear module of
HALO was used and the threshold for a positive cell was
defined based on the criteria used during manual pathology
review (Figure S1). Digital measurement allowed quantifica-
tion using both continuous measurements of the percentage
of positive cells, and dichotomisation at defined cut-offs (1%
and 20%). The 20% cut-off was selected prior to performing
survival analyses to identify similar number of cases as the
manual pathology review. The 1% cut-off was selected to be
a qualitative measurement of p53 expression in contrast to
no expression.
For SOX11 and Cyclin D1 staining, digital scoring using
the software HALO with the Cytonuclear module was per-
formed.
The number of Ki-67-positive cells was manually accessed
in areas with most cells positive for CD20. Ki-67 was anal-
ysed both as a continuous variable and dichotomised using a
30% positive cells cut-off, according to the clinical stan-
dard.21
Sequencing of TP53 gene
The DNA of formalin-fixed paraffin-embedded (FFPE) sam-
ples was extracted with High Pure FFPET DNA isolation kit
(Roche Diagnostics GmbH, Mannheim, Germany) according
to the manufacturer instructions. DNA quality was assessed
by quantitative polymerase chain reaction and samples with
less than six delta quantification cycles were sequenced.
The tumours from the BLISS cohorts (n = 72) were
sequenced on a TWIST cancer panel covering the exon parts
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of ~200 genes with capture probes. Detailed information is
found in Supplementary Information (Data S1; Sequencing
of the TP53 gene in a population-based material). TP53
mutations were validated using the Integrative Genomic
Viewer (IGV) software.22
In the present study, ion Torrent Next-Generation
Sequencing Technology was carried out according to previ-
ous protocol to assess TP53 mutations in eight additional
samples to complement data from the N-MCL2/3 clinical tri-
als.3
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences (SPSS) version 25.0 for Win-
dows (IBM Corp., Armonk, NY, USA) and R version 3.6 (R
Foundation for Statistical Computing, Vienna, Austria). Dif-
ferences were considered statistically significant at P < 005.
For a detailed description, see Supplementary Information
(Data S1; Statistical analysis).
Results
Patient characteristics and survival in the study material
Clinical information from the BLISS cohort was available for
140 patients and is shown in Table SII. Patients had a med-
ian (range) age at diagnosis of 71 (45–94) years, and a med-
ian OS of 41 years. The follow-up time using reversed
censoring (Kaplan–Meier estimator) was 54 years.
Male patients comprised 76% of the cohort. In all, 14%
of all tumours had Ki-67 ≥30% and 8% had blastoid/pleo-
morphic morphology. The Ki-67 ≥30% (HR 31, 95% CI
17–55; P < 0001) and blastoid/pleomorphic variants (HR
42, 95% CI 19–9; P < 0001) were associated with a worse
outcome in univariate Cox analysis. The follow-up time
using reversed censoring (Kaplan–Meier estimator) was
88 years.
Clinical information from the N-MCL2/3 cohort was
available for 216 patients and is shown in Table SIII. Patients
had a median (range) age at diagnosis of 57 (28–65) years
Fig 1. Overview of the clinical mantle cell lymphoma (MCL) material used in the present study. Three cohorts were used including (A) the pop-
ulation-based BLISS (Southern Sweden), (B) the Nordic MCL 2/3 trial cohort, and (C) F1 (Finnish cohort). IHC, immunohistochemistry, n,
number; TMA, tissue microarray.
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and a median OS and time to progression (TTP) of 128 and
99 years, respectively. In all, 73% were male, 22% were MIPI
high, 37% were high proliferative tumours, and 14% had
blastoid/pleomorphic morphology. As reported by Eskelund
et al.,3 blastoid morphology (HR 23, 95% CI 14–39;
P = 0001), high MIPI (HR 19, 95% CI 14–25; P < 0001)
and Ki-67 ≥30% (HR 18, 95% CI 11–28; P = 002) were
associated with poorer outcomes in univariate Cox analysis.
No clinical information was available from the Finnish MCL
cohort, which was only used to assess the frequency of p53-
positive cells.
Correlation between TP53 mutational status and p53
overexpression by pathology review
Among the 11 identified missense mutations in the BLISS
cohort, nine were classified as p53 positive based on manual
pathology review (Fig 2A). Thus, an accuracy of 82% was
achieved with sensitivity at 82% (nine of 11) and specificity
at 100% (61/61). In addition to the analyses on TMA, p53
staining was performed on whole tissue sections for five
mutated cases with moderate-to-low p53 expression in the
population-based cohort. A representative case where a posi-
tive subclone for p53 expression is shown can be seen in Fig-
ure S2.
To access the applicability in a different cohort, we used
the previously published sequencing data from the N-MCL2/
3 cohorts (n = 183). However, the same tissue was not avail-
able for IHC, and it was performed on separate patient mate-
rial (tissue for IHC vs. mainly bone marrow for sequencing).
Thus, we identified three cases with high p53 expression that
lacked missense mutations. In this data set, an accuracy of
71% was achieved with sensitivity at 75% (six of eight) and
specificity at 95% (58/61) using manual pathology review
(Fig 2B). Of note, full tissue sections were not available from
the N-MCL2/3 material and thus extended evaluation was
not possible to perform.
Comparison of manual and digital scoring of p53
overexpression IHC as a tool to determine TP53 missense
mutations
Correlation between digital pathology scoring (continuous
parameter) and manual pathology review was strong
(R2 = 086), independent of the cohorts. The individual val-
ues are presented in Table SIV. The regression coefficient
was similar between cohorts (BLISS cohort: 0029, N-MCL2/
3 cohort: 0023), allowing for comparison between scoring
systems. Receiver operating characteristic (ROC) analysis
based on p53 as a continuous variable from digital pathology
scoring, showed an area under the curve (AUC) value of
096 for the BLISS cohort (Fig 3).
Four cases with TP53 mutations that scored negative for
p53 expression (two in N-MCL2/3 and two in BLISS) had
<3% p53-positive cells. Three of them would be possible to
identify if a cut-off of 1% of positive cells would be selected
based on digital pathology scoring (see Table SVI). This cut-
off would adjust the specificity to 79% and sensitivity to
100% for missense mutations.
TP53 mutation frequency and correlation with survival
Mutational analysis showed that 21% (15/72) of patients
with MCL collected within the population-based cohort
BLISS had a mutated TP53 allele in the malignant cells
(Table SII). Detailed information about the mutations and
the clinical information of patients with mutated tumours
can be found in Supplementary Information (Tables SV and
SVI). Most aberrations 73% (11/15) were missense mutations
(Table SII). Consistent with previous reports, most of the
Fig 2. TP53 mutational status and manual scoring of p53 expression. Each square represents a tumour for which both immunohistochemistry
and sequencing data was available. Grey squares are identified as wild-type TP53 cases, Red squares are missense mutations, blue squares match
frameshift mutations and brown are classified as nonsense mutations. (A) BLISS cohort; (B) N-MCL2/3 clinical trials. [Colour figure can be
viewed at wileyonlinelibrary.com]
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mutations occurred in the DNA-binding domain of the
gene.23 R175H was the most frequent mutation, with three
patients reported to have the specific alteration (Figure S3).
The OS for patients with TP53-mutated MCL (n = 15) was
14 years (HR 31, 95% CI 15–64; P < 0001) compared to
62 years for unmutated MCL cases. Thus, 80% of the
patients harbouring TP53 mutations died in the first 5 years
after diagnosis, as visualised using Kaplan–Meier curve and
with log-rank statistics (Fig 4A).
Cases with missense mutations (n = 11) had no difference
in outcome compared to cases with other truncations and
frameshifts (n = 4), at 14 vs. 13 years (Table SII]). Due to
the few non-missense mutations, no further analysis on this
subgroup was conducted.
The increased number of samples sequenced for TP53 in the
N-MCL2/3 lead to similar results to those previously pub-
lished.3 The OS for patients with TP53 WT MCL was 14 years,
compared to 24 years (HR 88, 95% CI 5–153; P < 0001) for
mutated MCL. Patients carrying TP53-mutated tumours also
relapsed faster (HR 117, 95% CI 68–203; P < 0001) than
patients with WT MCL tumours (Table SIII).
p53 overexpression and correlation to survival
The overall frequency of p53 protein overexpression was
13%, consistent with previous reports.10,24 The variation
among the individual cohorts was minor with 14% (18/133)
in BLISS, 11% (11/100) among N-MCL2/3, and 155% (13/
84) among Finnish MCL patients (F1). Clinical information
for the BLISS patients with tumour p53 overexpression can
be found in the Supplementary Information (Table SVI).
Patients in the population-based cohort (BLISS) with no/
low p53 expression in the tumour cells had a median survival
of 45 years (Table SII), whereas patients with high p53
expression based on manual pathology review had a median
overall survival of 09 years (HR 31, 95% CI 17–57;
P < 0001). The difference in survival between patients with
high and low p53 expression is visualised in Fig 4B together
with the log-rank statistics. The same difference was seen for
the N-MCL2/3 cohort (Fig 5; Table SIII), although the med-
ian survival of p53 low cases is longer due to the difference
in treatment and age and fitness of patients at diagnosis.
p53 as a continuous variable in all cohorts, assessed
through digital pathology, was significantly associated with
poor OS (HR 102, 95% CI 101–103, P < 0001 for OS in
BLISS; HR 102, 95% CI 1003–103, P < 005 for OS in N-
MCL2/3; and HR 102, 95% CI 101–103, P < 0001 for
TTP in N-MCL2/3).
Correlation of TP53 mutations and p53 expression with
high-risk parameters
It has previously been proposed that SOX11-negative cases
may represent indolent MCL that gain TP53 mutations and
Fig 3. Receiver operating characteristic (ROC) analysis for N-MCL2/3 and/or BLISS cohorts. Area under the curve (AUC) was estimated using
the digital pathology scoring as a continuous measurement of the percentage of positive cells in the different cohorts. AUC value for BLISS was
096; AUC value for N-MCL2/3 was 088, whereas for both cohorts combined, the AUC value was 092. [Colour figure can be viewed at wileyon
linelibrary.com]
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undergo blastoid transformation.25 Although these cohorts
represent nodal, symptomatic MCL, we evaluated the associ-
ations between SOX11 and p53/TP53 aberrations but found
no significance (data not shown). Also, the association
between age and p53/TP53 aberrations was investigated but
showed no significance (Figure S4).
Although non-classical morphology, Ki-67 and p53 were
all associated with worse survival (data not shown), in multi-
variate analysis only p53 expression remained significant (HR
21, 95% CI 1001–43; P < 005) in the BLISS cohort.
p53 overexpression was strongly associated with more
aggressive variants of MCL, with higher p53 expression
Fig 4. Prognostic impact (overall survival) of TP53 mutations (n = 72) and p53 overexpression (n = 133) in BLISS. Samples were scored based
on the targeted sequencing analysis and the Kaplan–Meier estimates were calculated and plotted for (A) mutations and (B) p53 overexpression
based on manual pathology review. Log-rank statistics were used to assess the prognostic significance. [Colour figure can be viewed at wileyon
linelibrary.com]
Fig 5. Prognostic impact of p53 overexpression (n = 100) in N-MCL2/3. Samples were scored based on manual pathology review and the
Kaplan–Meier estimates were calculated and plotted for (A) overall survival and (B) time to progression. Log-rank statistics were used to assess
the prognostic significance. [Colour figure can be viewed at wileyonlinelibrary.com]
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observed in cases with high Ki-67 and non-classic variants
(P < 005) (Fig 6; Tables SII and SIII). Albeit the strong cor-
relation, patients with high-risk variants do not exclusively
display p53 abnormalities. Patient-specific information on
treatment (when available), proliferation, mutational status,
p53 expression and outcome is shown for the population-
based cohort BLISS in Table SVI.
Discussion
The frequency of TP53 aberrations in the population-based
cohort was 21%, consistent with previous studies, where 7–
31% of patients had aberrations in TP53.3,26,27 TP53 muta-
tions conferred a threefold increased risk of death in the
population-based material analysed. Most mutations were
missense and occurred in the “hot spot” regions of the gene
binding domain. Updated data from the N-MCL2/3 cohort
showed a 88-times increased risk of death with TP53 aberra-
tions, similar to the original report.3
Although the impact of TP53 mutations in MCL is well
known,3,28 p53 overexpression associated with missense
mutations is less well studied, and little is known on the
impact on outcome in MCL. In the present study, where
material from both population-based and clinical trials were
used (n = 317 patients), 13% of MCL expressed p53 at diag-
nosis, similar to previous studies.10,24 It is widely accepted,
although poorly understood, that mutations in TP53 will
confer a high stability to the p53 mutated protein, as
opposed to WT p53, leading to accumulation of the protein
in the cells.11,29,30 In our present study, assessment of p53
expression correctly identified the majority of the missense
mutations, with an AUC value of 096 for the population-
based material.
The correlation between manual and digital scoring meth-
ods was high and the overall value was R2 = 086 (n = 317). In
clinical routine, p53 is considered positive when >30% of the
nuclei are strongly stained for p53. However, in some cases a
focal expression of p53 can be found while the overall fre-
quency is <30%. These cases may be considered negative by
the pathologists, but a subclone that expresses p53 is reported.
Subsequently, the predictive power of both techniques to assess
missense mutations in TP53 was high. Pathology review pro-
vided an accuracy at 82%, with a 100% specificity, and 82%
sensitivity when whole tissue section could be used to further
evaluate mutated cases that had <30% p53-positive cells based
on TMA analysis. This emphasises the need to use full tissue
sections for clinical evaluation and risk scoring. For the clinical
trial cohort (N-MCL2/3), where different tissue was used for
IHC and sequencing, accuracy reached 71%.
Digital pathology scoring provides the possibility to anal-
yse p53 expression as a continuous parameter and allow
qualitative assessment of p53 with a cut-off at 1% positive
cells. With this methodology, 100% sensitivity was reached,
but with an overall lower accuracy of 79%.
Fig 6. Correlation between p53 scoring, TP53 mutation, morphology variant, Ki-67 and MIPI. (A) BLISS; (B) N-MCL2/3; (C) F1 cohort. Each
column corresponds to one patient. High-risk variants are enriched in mutated and/or overexpressing cases, although, they are not exclusive of
patients carrying mantle cell lymphoma tumours with aberrations on p53. [Colour figure can be viewed at wileyonlinelibrary.com]
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It is known that patients with MCL are molecularly
diverse,31 with TP53 aberrations being one of the strongest risk
factors.3 Thus, IHC analysis of p53 can serve multiple pur-
poses. Stand-alone, it will identify patients with a shorter OS.
It can also be used as a screening method to select patients for
further genomic TP53 analysis. Targeted sequencing in routine
clinical practice is not yet implemented, and selection of
patients constitutes an approach to reduce the practical and
financial burden of a patient-wide screening using next-gener-
ation sequencing. Using p53 as a surrogate marker has already
been suggested for other malignancies with a similar accuracy
of ~90%.14,32,33 IHC brings the advantage that cases with a
mutated subclone can be visualised. Such mutated cases may
be challenging to identify through sequencing due to low allele
frequency. This makes IHC a relevant technique to screen lar-
ger areas and shape genomic analysis for more accurate study
of mutations in cases with clearly heterogeneity and clones
arising within the tumour.
Our present study does not come without limitations,
including the low absolute number of p53-positive cases
available for analysis and the fact that only missense muta-
tions can be identified using p53 overexpression. By using
this technique, we failed to identify two out of 11 mis-
sense mutations. Technical factors such as age of the
paraffin block, fragmentation of DNA could possibly
account for the difference in results, but also unknown
biological factors that influence the degradation of the p53
protein.
p53 expression has previously been associated to blastoid
morphology and Ki-67.5,6,34 However, in the present study we
use IHC information from a large cohort of 233 patients to
associate p53 expression also to outcome. We show that there
was a significant number of MCLs with TP53 mutations and/
or p53 expression among MCL with non-classical morphology
(P < 005) and high Ki-67 expression (P < 005). In total, 52
patients had MCL with either TP53 mutations or p53 expres-
sion, of these, 22 were non-classic and 27 highly proliferative.
Thus, p53 is independently associated with survival, and only
half of the patients carrying mutations shown other high-risk
clinicopathological factors.4,5,10
TP53 mutations are a key independent prognostic factor
for patients with MCL, with an OS related HR of 3 in our
present population-based material. Due to the current lack of
routine target sequencing for TP53 mutations in the clinic,
fast and reliable IHC alternatives are in high demand for
improved patient stratification. Our present results show that
p53 IHC analysis can be used as a surrogate marker for the
detection of missense mutations. IHC analysis of p53 can
benefit clinical workflows where sequencing capability is lim-
ited or not available and optimise treatment decision-mak-
ing, as it identifies high-risk patients independent of
treatment regimen, age and aggressive morphology variants
to allow stratification of primary MCL patients using a com-
bined MIPI according to previous suggestion.35
To date, although it is known that rituximab + high dose
cytarabine is not sufficient for these patients, it remains to be
determined what these patients should be offered. The
recently published AIM trial9 showed promising results for
treating TP53-mutated patients, which included ibrutinib in
combination with venetoclax. Allogenic stem-cell transplanta-
tion could, additionally, be an option for these patients with
adverse outcomes.36 Ongoing clinical trials with different
combinations including ibrutinib and/or venetoclax will,
hopefully, present more options for this challenging sub-
group of patients.
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